333 results on '"Ferrarotto, R"'
Search Results
2. Prognostic Value of Time To Progression vs. Tumor Volume Doubling Time in Patients with Adenoid Cystic Carcinoma Metastatic To The Lung
3. Efficacy and Tolerability of Vascular Endothelial Growth Factor Receptor Inhibitors (VEGFRi) for Recurrent/Metastatic Adenoid Cystic Carcinoma (R/M ACC): a Systematic Review and Meta-Analysis
4. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
5. Fractionated Stereotactic Radiotherapy in the Management of Dural Recurrence of Olfactory Neuroblastoma
6. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study
7. Current management and future challenges in salivary glands cancer
8. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay
9. The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours
10. Stereotactic Body Radiation Therapy (SBRT) Following Salvage Surgery for Previously Irradiated Head and Neck Cancer
11. Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.
12. 900P Notch inhibitor AL101 prior to surgery in patients (pts) with Notch1 activated adenoid cystic carcinoma (ACC): Safety and efficacy in a window of opportunity study.
13. 1789P The gamma secretase inhibitor AL101 combined with other drugs for dual targeting of Notch dysregulated tumors
14. 904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort
15. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
16. Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.
17. 903P AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
18. 909P TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype
19. 907P Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II
20. 908P Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
21. Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases.
22. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy
23. Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage
24. OA03.08 Trilaciclib Reduces the Need for Growth Factors and Red Blood Cell Transfusions to Manage Chemotherapy-Induced Myelosuppression
25. Comparison of Prospective, Longitudinal Swallowing Function after Primary Intensity-Modulated Proton Therapy (IMPT) or Transoral Robotic Surgery (TORS) for Oropharyngeal Squamous Cell Carcinoma
26. Risk and Predictors of Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors Treated with Definitive Radiotherapy: A Retrospective Cohort Study among 1,988 Survivors
27. Concurrent Nivolumab And Ipilimumab With Brain Stereotactic Radiosurgery For Brain Metastases From Non-Small Cell Lung Cancer: A Phase I Trial
28. Patterns Of Loco-Regional Failure And Outcomes After Intensity Modulated Radiation Therapy For Unresectable Anaplastic Thyroid Cancer
29. 562P Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex
30. 919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
31. Intensity Modulated Proton Therapy (IMPT) to the Parotid Gland: A Seven-Year Experience
32. Reirradiation with SBRT, IMRT and Proton Therapy for Recurrent Oropharynx Squamous Cell Carcinoma: Efficacy and Toxicity Outcomes
33. Integrative proteomic and transcriptomic analysis define adenoid cystic carcinoma subgroups with distinct therapeutic targets
34. Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting
35. Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy
36. Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy
37. A prospective evaluation of health-related quality of life after skull base re-irradiation
38. ACCURACY a phase (P) II trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): Preliminary safety and efficacy data
39. Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)
40. Surgery Followed by Cornea-Sparing Treatment Approach with Proton Therapy Reduces Orbital Exenteration for Cancer Patients with Periorbital Malignancies
41. Head and Neck Adenoid Cystic Carcinoma: Focus on Outcomes of Intensity Modulated Proton Therapy
42. Local Regional Patterns of Failure Following Postoperative IMRT for Anaplastic Thyroid Cancer
43. Detection of Circulating Tumor Cells During Radiation Therapy in Patients with Head and Neck Cancer
44. Outcomes of Intensity Modulated Irradiation for Sinonasal Cancers in the Modern Era
45. Outcomes of Patients Diagnosed With Carcinoma Metastatic to the Neck From an Unknown Primary Source and Treated With Intensity-Modulated Radiation Therapy
46. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling
47. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors
48. Second Primary Malignancies in Head and Neck Cancer Patients Treated With Definitive Radiation Therapy
49. Second Primary Malignancies in Head and Neck Cancer Patients Treated with Definitive Radiotherapy
50. Long-Term Patient Reported Symptoms and Quality of Life in Patients >65 Following Radiation Therapy for Early Stage Glottic Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.